There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > RAGE


RAGE Molecule Information

Name:Advanced glycosylation end product-specific receptor
Target Synonym:RAGE;AGER;Advanced glycosylation end product-specific receptor;Receptor for advanced glycosylation end products
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase ?

RAGE Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AGR-H5253 Human Human RAGE / AGER Protein, Fc Tag

RAGE Part of Bioactivity data

Human RAGE, Fc TagHuman RAGE, Fc Tag (Cat. No. AGR-H5253) ELISA bioactivity

Immobilized Human HMGB1, His Tag (Cat. No. HM1-H5220) at 5 μg/mL (100 μL/well) can bind Human RAGE, Fc Tag (Cat. No. AGR-H5253) with a linear range of 0.078-1.25 μg/mL (QC tested).

RAGE Molecule Synonym Name


RAGE Molecule Background

Advanced glycosylation end product-specific receptor (AGER) is also known as RAGE, and is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. AGER is highly expressed in endothelial cells. AGER mediates interactions of advanced glycosylation end products (AGE), and also accumulates in vascular tissue in aging and at an accelerated rate in diabetes, as well as acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGER / RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

RAGE References

RAGE Related Molecule

RAGE Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Azeliragon TTP-488; PF-04494700; PF-4494700,PF04494700,TTP488 Phase Ⅲ vTv Therapeutics Alzheimer's disease (AD) Details
Tenilsetam CAS-997 Phase Not Specified Sanofi Dementia Details
TRC-041266 TRC-041266 Phase Ⅲ Torrent Pharmaceuticals Chronic heart failure Details
TRC-4186 TX-41XX; TRC-4186 Phase Ⅱ Torrent Pharmaceuticals Diabetic complications, Heart failure Details
Alagebrium chloride ALT-711 Phase Ⅲ Synvista Therapeutics Cardiovascular disorders, Erectile dysfunction (ED), Hypertension, Heart failure Details
TTP-4000 TTP-4000 Phase Ⅰ vTv Therapeutics Alzheimer's disease (AD) Details

This web search service is supported by Google Inc.